Enitociclib diminishes the BM-derived stromal–mediated survival advantage in KMT2A-r leukemic cells. (A) Four KMT2A-r leukemic cell lines were cultured with and without BMSCs and treated with enitociclib for 72 hours. Data represented as means ± standard error of the mean (SEM) from 3 independent biological experimental replicates. (B) Four KMT2A-r leukemic cell lines were cultured with and without 10% BM-CM and treated with enitociclib for 72 hours. Data represented as means ± SEM from 3 independent biological experimental replicates. For 2 group comparisons, a Student t test was used. A P value <.05 was considered statistically significant. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.